Insider Selling: Precigen (NASDAQ:PGEN) COO Sells $224,589.54 in Stock

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 32,739 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $6.86, for a total transaction of $224,589.54. Following the completion of the transaction, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at approximately $3,189,982.32. The trade was a 6.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Stock Performance

Shares of PGEN opened at $7.23 on Monday. The company has a 50-day simple moving average of $5.23 and a two-hundred day simple moving average of $4.50. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. The firm has a market capitalization of $2.58 billion, a PE ratio of -6.95 and a beta of 1.02. Precigen, Inc. has a one year low of $1.70 and a one year high of $7.26.

Precigen (NASDAQ:PGEN) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm had revenue of $54.98 million for the quarter, compared to the consensus estimate of $27.98 million. The company’s revenue for the quarter was up 6322.7% compared to the same quarter last year. On average, analysts anticipate that Precigen, Inc. will post 0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on PGEN shares. Citizens Jmp increased their price objective on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Wall Street Zen raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, HC Wainwright lifted their price target on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently added to or reduced their stakes in the stock. Alpine Woods Capital Investors LLC bought a new position in shares of Precigen during the second quarter valued at $1,309,000. BlackRock Inc. bought a new position in Precigen in the 2nd quarter worth about $97,737,000. Deutsche Bank AG bought a new position in Precigen in the 2nd quarter worth about $1,141,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Precigen during the 2nd quarter valued at about $307,000. Finally, SCS Capital Management LLC purchased a new stake in Precigen during the 2nd quarter valued at about $244,000. 33.51% of the stock is owned by institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.